Hochmair M.JMorabito AHao DYang C.-TSoo R.ACHIH-HSIN YANGGucalp RHalmos BWang LMärten ACufer T.2020-05-262020-05-2620191479-6694https://www.scopus.com/inward/record.uri?eid=2-s2.0-85071633846&doi=10.2217%2ffon-2019-0346&partnerID=40&md5=ad9caa925250559e398aba9893acc8bdhttps://scholars.lib.ntu.edu.tw/handle/123456789/494902Aims: Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer who received sequential afatinib/osimertinib in the real-world GioTag study. Patients & methods: Patients had T790M-positive disease following first-line afatinib and received osimertinib treatment (n = 203). Primary outcome was TTF. The OS analysis was exploratory. Results: Median OS was 41.3 months (90% CI: 36.8-46.3) overall and 45.7 months (90% CI: 45.3-51.5) in patients with Del19-positive tumors (n = 149); 2-year survival was 80 and 82%, respectively. Updated median TTF with afatinib and osimertinib was 28.1 months (90% CI: 26.8-30.3). Conclusion: Sequential afatinib/osimertinib was associated with encouraging OS/TTF in patients with EGFR T790M-positive non-small-cell lung cancer, especially in patients with Del19-positive tumors. Trial registration number: NCT0337077. ? 2019 Maximilian J Hochmair.afatinib; NSCLC; osimertinib; sequential; T790M[SDGs]SDG3acrylamide derivative; afatinib; aniline derivative; EGFR protein, human; epidermal growth factor receptor; osimertinib; genetics; human; mutation; non small cell lung cancer; pathology; Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Mutationreview10.2217/fon-2019-0346313706982-s2.0-85071633846